- Five Prime has a nascent pipeline.
- The field of FGF inhibitors in which it is working is not an easy area.
- It will be competing with larger pharmaceuticals that have large resources and are also ahead in the race.
- Accumulated losses of $144.3 million – further stock dilution expected.
- The market seems to be responding without proper attention to the negatives.